<DOC>
	<DOCNO>NCT02875548</DOCNO>
	<brief_summary>This study provide continue availability tazemetostat single agent subject complete participation antecedent tazemetostat study ( either monotherapy combination therapy ) . In addition , long-term safety overall survival collect .</brief_summary>
	<brief_title>Tazemetostat Rollover Study ( TRuST ) : An Open-Label Rollover Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>1 . Has demonstrate clinical benefit treatment tazemetostat . 2 . Is currently receive tazemetostat either monotherapy combination approve drug ( ) investigational agent ( ) Epizymesponsored clinical trial clinical trial conduct tazemetostat sponsor Epizyme ( include limit , Investigator initiate trial ) . For subject combination therapy , therapeutic ( ) must complete provide source Epizyme 3 . Has provide sign write informed consent 4 . Has life expectancy &gt; 3 month 5 . Has adequate hematopoietic , coagulation , renal hepatic function . Subject must remain eligible continued treatment tazemetostat accord eligibility treatment criterion antecedent study . 6 . For French subject : Is either affiliated beneficiary social security category . 7 . Female subject childbearing potential must : Have negative betahuman chorionic gonadotropin ( Î²hCG ) pregnancy test time study entry within 14 day prior plan first dose investigational product , Agree use effective contraception 30 day follow last dose investigational product male partner use condom Practice true abstinence Have male partner vasectomize . 8 . Male subject female partner childbearing potential must : Be vasectomize , Agree use condom 30 day follow last dose investigational product , Have female partner NOT childbearing potential . 1 . Has interruption tazemetostat dose &gt; 14 day antecedent clinical study start rollover study . 2 . Has malignancy one receiving tazemetostat Exception : Subject diseasefree prior malignancy 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . 3 . Is unwilling exclude grapefruit juice , Seville oranges grapefruit diet food contain fruits time enrollment study . 4 . Is currently take prohibit medication ( ) . 5 . Is unable take oral medication , malabsorption syndrome uncontrolled gastrointestinal condition ( e.g. , nausea , diarrhea vomit ) might impair bioavailability tazemetostat 6 . Has uncontrolled intercurrent illness include , limited , uncontrolled infection , psychiatric illness/social situation would limit compliance study requirement . 7 . For female subject childbearing potential : Is pregnant nurse 8 . Has permanently discontinue tazemetostat therapy due adverse event , intolerance treatment failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>